A hidden risk factor you cannot exercise away
Tucked within the genetic code of roughly one in five people is a cholesterol particle called lipoprotein(a) that quietly raises the risk of heart attack and stroke, indifferent to the salads eaten or the miles run. Unlike the familiar landscape of good and bad cholesterol, Lp(a) is largely inherited, stable across a lifetime, and invisible to standard screening panels—a silent variable in the equation of cardiovascular health. Now, after decades of limited options, gene-silencing therapies are showing dramatic reductions in clinical trials, bringing this hidden risk factor to the threshold of mainstream medicine.
- Millions of health-conscious people may unknowingly carry elevated Lp(a), a genetically fixed cholesterol particle that statins cannot tame and lifestyle changes cannot reach.
- The particle's double threat—promoting arterial plaque and triggering blood clotting—compounds other cardiovascular risks, helping explain why some people develop heart disease despite doing everything right.
- Standard cholesterol tests don't measure Lp(a) at all, and in countries like Australia, patients must pay out of pocket for a test that international guidelines now recommend everyone have at least once.
- Gene-silencing drugs from Novartis, Amgen, and Eli Lilly are slashing Lp(a) levels by 80–90% in trials, a leap so significant it has reordered research priorities across the cardiovascular field.
- The field now waits on pivotal trial results to confirm whether lower Lp(a) levels translate to fewer heart attacks and strokes—a finding that could make routine Lp(a) screening standard practice worldwide.
You can eat well, exercise faithfully, and still carry a hidden cardiovascular threat. Lipoprotein(a)—Lp(a)—is a cholesterol particle most people have never heard of, yet it operates by rules that make it uniquely difficult to ignore or outrun. Structurally close to LDL, the familiar "bad" cholesterol, Lp(a) carries an extra protein on its surface that makes it more prone to building up inside artery walls and promoting blood clots. Large-scale studies and international guidelines now recognize it as a genuine risk factor for heart attacks, strokes, and aortic valve disease—yet it remains absent from routine cholesterol panels.
What sets Lp(a) apart is its genetic stubbornness. Between 70 and 90 percent of a person's Lp(a) level is inherited, determined primarily by a single gene, and it stays essentially stable from early adulthood onward. Diet, exercise, and body weight—the usual tools of cardiovascular self-care—have almost no effect on it. Small fluctuations occur around menopause or with kidney disease, and levels vary somewhat by sex and ethnicity, but the core reality is fixed: for most people, Lp(a) is simply the hand genetics dealt them. Risk rises continuously with level, and the danger intensifies when Lp(a) is combined with elevated LDL or systemic inflammation, helping explain why some individuals develop heart disease despite otherwise favorable profiles.
Treatment options have long been frustratingly thin. Statins don't lower Lp(a) and may nudge it slightly upward, though they remain essential for overall cardiovascular protection. Newer PCSK9 inhibitors offer only modest reductions of 15 to 30 percent. That picture is changing rapidly. Novartis, Amgen, Eli Lilly, and others are developing gene-silencing drugs that switch off Lp(a) production at the source rather than clearing it after the fact—early trials show reductions of 80 to 90 percent, a result that has made Lp(a) a sudden priority in cardiovascular research.
For individuals, the immediate question is whether to get tested. A specific blood test is required, as Lp(a) doesn't appear on standard panels. In Australia, the test costs roughly 25 to 80 dollars out of pocket. Guidelines recommend at least one measurement in adulthood, especially for anyone with a family history of early heart disease. A high result need not be paralyzing—cardiologists frame it as one piece of a larger picture, and managing every controllable risk factor becomes even more important when Lp(a) is elevated. If ongoing trials confirm that the new therapies reduce actual cardiac events and not just lab numbers, routine screening and treatment could soon become standard care. For now, awareness and a conversation with a doctor are the most actionable first steps.
You can eat well, exercise regularly, maintain a healthy weight, and still carry a hidden risk factor for heart attack or stroke. It's called lipoprotein(a)—Lp(a) for short—and most people have never heard of it. Unlike the familiar categories of "good" and "bad" cholesterol that dominate health conversations, this lesser-known particle operates by different rules. It can silently elevate your cardiovascular risk regardless of how carefully you live, which is precisely why researchers and pharmaceutical companies have begun paying serious attention to it.
Lp(a) is structurally similar to LDL cholesterol, the "bad" kind everyone worries about, but with a crucial difference: it carries an additional protein called apolipoprotein(a) attached to its surface. That extra protein appears to be the problem. It makes the particle more likely to accumulate as fatty deposits inside artery walls and may also trigger blood clotting. Together, these mechanisms increase the likelihood of cardiovascular disease—the umbrella term for heart attacks, strokes, and related conditions. Large-scale studies and international medical guidelines now recognize Lp(a) as a legitimate risk factor, yet it remains absent from routine cholesterol screening.
What makes Lp(a) particularly vexing is its genetic nature. Between 70 and 90 percent of the variation in a person's Lp(a) levels is inherited, controlled primarily by the LPA gene, which determines the structure of that problematic extra protein. This means your Lp(a) level is largely set early in life and remains stable throughout adulthood. Diet, exercise, and body weight—the levers most people can pull to improve their health—have minimal effect on it. Menopause, kidney disease, and other factors can cause small fluctuations, and levels vary slightly by sex and ethnicity, but the fundamental reality is that you cannot exercise or eat your way to lower Lp(a). For many people, it is simply the hand they were dealt genetically.
The cardiovascular risk rises in a dose-dependent fashion. Long-term studies show that as Lp(a) levels climb, so does the risk of heart attacks, strokes, and aortic valve disease. The relationship is continuous—there is no safe threshold where risk suddenly drops. Moreover, Lp(a) compounds other risks. Someone with both elevated LDL cholesterol and high Lp(a) faces greater danger than someone with only one of those problems. Interestingly, for people with higher Lp(a), cardiovascular risk tends to spike when inflammation is also elevated, which helps explain why some individuals develop heart disease despite otherwise favorable health profiles and good lifestyle choices.
Until recently, treatment options were sparse. Standard cholesterol-lowering medications like statins do not reduce Lp(a) and may even increase it slightly—though statins still reduce overall cardiovascular risk and remain essential. Some newer drugs called PCSK9 inhibitors can lower Lp(a), but only modestly, by around 15 to 30 percent. That limitation is changing. Novartis, Amgen, Eli Lilly, and other major pharmaceutical companies are racing to develop drugs that work through an entirely different mechanism: gene silencing. Rather than trying to clear Lp(a) from the bloodstream after the liver produces it, these medicines essentially switch off production at the source. Early clinical trials show reductions of 80 to 90 percent—a dramatic improvement that has suddenly made Lp(a) a priority in cardiovascular research.
The practical question for most people is whether they should be tested. Lp(a) does not appear on standard cholesterol panels, so a specific blood test is required. In Australia, Medicare does not cover this test, meaning patients pay out of pocket—typically between 25 and 80 Australian dollars, plus consultation costs. International guidelines now recommend that adults have their Lp(a) measured at least once, particularly those with a family history of early heart disease or unexplained cardiovascular risk. Because levels are genetically determined and stable, a single measurement is usually sufficient.
Learning you have high Lp(a) can feel discouraging, especially given the current scarcity of direct treatment options. But cardiologists emphasize viewing it as one piece of a larger puzzle. You still control numerous factors that influence overall cardiovascular risk: LDL cholesterol, blood pressure, smoking status, physical activity, diet quality, and management of conditions like diabetes. For people with elevated Lp(a), managing these modifiable factors may be even more critical. The field is moving rapidly. If the current generation of clinical trials demonstrates that the new gene-silencing therapies actually reduce heart attacks and strokes—not just Lp(a) levels—testing and treatment protocols could become standard practice. For now, awareness is the first step, and a conversation with your doctor about testing makes sense if you have reason to suspect elevated risk.
Notable Quotes
For people with elevated Lp(a), managing modifiable cardiovascular factors may be even more important— International cardiovascular guidelines
The Hearth Conversation Another angle on the story
Why does Lp(a) matter if we can't do much about it yet?
Because it explains why some people have heart attacks despite doing everything right. It's genetic, stable, and independent of lifestyle. That's the whole point—it's a risk factor you can't exercise away.
So if statins don't work on it, why are people still taking them?
Statins still reduce overall cardiovascular risk through other mechanisms. But for someone with high Lp(a), statins alone won't address that particular threat. That's why the new drugs are so significant.
These gene-silencing drugs—how do they actually work differently?
Instead of trying to remove Lp(a) from your blood after your liver makes it, they tell your liver to make less in the first place. It's prevention at the source rather than cleanup after the fact.
If 70-90% of Lp(a) is genetic, does that mean it's completely unchangeable?
Mostly, yes. But that 10-30% that isn't purely genetic can shift slightly with menopause, kidney disease, or other factors. The point is you can't diet your way to lower it.
What happens to someone who discovers they have high Lp(a) right now, before these new drugs are available?
They focus on everything else they can control—LDL cholesterol, blood pressure, smoking, exercise, diet. Those factors still matter enormously. High Lp(a) doesn't mean you're doomed; it means you need to be more vigilant about the things you can change.
When will we know if these new drugs actually prevent heart attacks?
That's the crucial question. The trials are ongoing. If they show real cardiovascular benefit, not just lower Lp(a) numbers, then testing and treatment could become routine within a few years.